NattoPharma, Glanbia Nutritionals Sign Exclusive Distribution Agreement

NattoPharma signed an exclusive agreement with Glanbia Nutritionals for MenaQ7® PURE distribution in the United States and Canada.

HØVIK, Norway—NattoPharma signed an exclusive agreement with Glanbia Nutritionals for MenaQ7® PURE distribution in the United States and Canada.

"The market for vitamin K2 as MK-7 is clearly expanding as the scientific evidence of its ability to promote bone and cardiovascular health continues to accumulate," said Hogne Vik, CEO, NattoPharma. “As vitamin K2 awareness has been rapidly growing, NattoPharma has been fielding an influx of inquiries. Glanbia Nutritionals' broad and deep customer base will benefit from this vital new offering, which will further enhance NattoPharma’s U.S. presence."

NattoPharma's MenaQ7® PURE is produced in a European pharmaceutical manufacturing facility and is fully validated by numerous human clinical studies, as well as in-vivo and in-vitro research.

In June, MenaQ7 was first introduced to the U.S. market.

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish